[Source: Thorax, full page: (LINK). Abstract, edited.]
Early nasal microbiota and acute respiratory infections during the first years of life
Laura Toivonen 1,2, Kohei Hasegawa 1, Matti Waris 3, Nadim J Ajami 4, Joseph F Petrosino 4, Carlos A Camargo Jr 1, Ville Peltola 2
Author affiliations: 1 Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; 2 Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland; 3 Virology Unit, Institute of Biomedicine, University of Turku, Turku, Finland; 4 Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
Correspondence to Dr Laura Toivonen, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; email@example.com
Emerging evidence shows that airway microbiota may modulate local immune responses, thereby contributing to the susceptibility and severity of acute respiratory infections (ARIs). However, there are little data on the longitudinal relationships between airway microbiota and susceptibility to ARIs in children.
We aimed to investigate the association of early nasal microbiota and the subsequent risk of ARIs during the first years of life.
In this prospective population-based birth-cohort study in Finland, we followed 839 healthy infants for ARIs from birth to age 24 months. Nasal microbiota was tested using 16S rRNA gene sequencing at age 2 months. We applied an unsupervised clustering approach to identify early nasal microbiota profiles, and examined the association of profiles with the rate of ARIs during age 2–24 months.
We identified five nasal microbiota profiles dominated by Moraxella, Streptococcus, Dolosigranulum, Staphylococcus and Corynebacteriaceae, respectively. Incidence rate of ARIs was highest in children with an early Moraxella-dominant profile and lowest in those with a Corynebacteriaceae-dominant profile (738 vs 552/100 children years; unadjusted incidence rate ratio (IRR), 1.34; 95% CI 1.16 to 1.54; p < 0.001). After adjusting for nine potential confounders, the Moraxella-dominant profile-ARI association persisted (adjusted IRR (aIRR), 1.19; 95% CI 1.04 to 1.37; p = 0.01). Similarly, the incidence rate of lower respiratory tract infections (a subset of all ARIs) was significantly higher in children with an early Moraxella-dominant profile (aIRR, 2.79; 95% CI 1.04 to 8.09; p = 0.04).
Moraxella-dominant nasal microbiota profile in early infancy was associated with an increased rate of ARIs during the first 2 years of life.
LT collected the data, obtained the funding, carried out the statistical analysis, drafted the initial manuscript and approved the final manuscript as submitted. KH carried out the statistical analysis, reviewed and revised the initial manuscript, and approved the final manuscript as submitted. MW carried out the virological analysis and DNA extractions, reviewed and revised the manuscript, and approved the final manuscript as submitted. NA and JFP generated the microbiome data, carried out the initial statistical analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. CAC critically reviewed and revised the initial manuscript, and approved the final manuscript as submitted. VP conceptualised and designed the study, obtained the funding, supervised the conduct of the study, reviewed and revised the manuscript, and approved the final manuscript as submitted.
This work was supported by the University of Turku; the Abo Akademi University; the Turku University Hospital; the Academy of Finland (Grant nos. 123571, 140251 and 277535); the Finnish Medical Foundation; the Päivikki and Sakari Sohlberg Foundation; the Foundation for Pediatric Research; Research Funds from Specified Government Transfers, Hospital District of Southwest Finland; the Foundation of the Finnish Anti-Tuberculosis Association; the Tampere Tuberculosis Foundation; the Allergy Research Foundation; the Emil Aaltonen foundation; the Maud Kuistila Memorial Foundation; the Orion Research Foundation; the Paulo Foundation; the Väinö and Laina Kivi Foundation and the Finnish Cultural Foundation.
Patient consent for publication
The STEPS study was found ethically acceptable by the Ministry of Social Affairs and Health (STM 1575/2008, STM 1838/2009) and the Ethics Committee of the Hospital District of Southwest Finland (19.2.2008 §63, 15.4.2008 §134, 19.4.2011 §113).
Provenance and peer review
Not commissioned; externally peer reviewed.
Data sharing statement
Data are available upon reasonable request.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information: © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords: Microbiota; Respiratory Infections.